.svg)
17-OHP: A Steroid Bridge Between Cortisol and Androgens
17-hydroxyprogesterone is a steroid building block made mostly by the adrenal glands, with smaller amounts from the ovaries and testes. It sits midway in the body's pathway for making cortisol, the main stress hormone. The molecule is created when progesterone is modified by a specific adrenal enzyme (17α-hydroxylase, CYP17A1). A blood test measures how much 17-hydroxyprogesterone is circulating at a given time.
This biomarker matters because it lies at a crossroads between cortisol production and androgen formation. Under normal conditions, the adrenal enzyme 21-hydroxylase (CYP21A2) converts 17-hydroxyprogesterone toward cortisol (via 11-deoxycortisol). If that step slows, 17-hydroxyprogesterone can build up and be redirected into androgen pathways (such as androstenedione and testosterone) through 17,20-lyase activity. Therefore, its level reflects the flow and balance of adrenal steroid synthesis and the influence of pituitary signaling (ACTH). In practice, measuring 17-hydroxyprogesterone helps clinicians understand adrenal enzyme function and the balance between stress-hormone and androgen production across different life stages.
Why Measuring an Enzyme Bottleneck Matters
17‑hydroxyprogesterone (17‑OHP) is a steroid "bridge" molecule made by the adrenal glands and gonads on the way to cortisol and androgens. Because it sits at a key junction in steroid synthesis, its blood level reveals how well the adrenal cortex is working, how ACTH is driving it, and whether hormone traffic is being diverted toward excess androgens. It's central in newborn screening and in evaluating hirsutism, irregular cycles, infertility, and adrenal disorders.
Reading 17-OHP by Age, Phase, and Direction
Typical reference intervals vary by age, time of day, menstrual phase, and pregnancy. Newborns start high, then fall over weeks; adults are generally low, with a rise in the luteal phase and in pregnancy; morning values run higher than afternoon. For most, values clustered in the phase‑appropriate middle of the range fit healthy physiology; persistent extremes warrant attention.
When values run low, they often reflect reduced adrenal steroid output—seen with primary adrenal insufficiency or adrenal suppression from glucocorticoids—leading to fatigue, low blood pressure, salt craving, and weight loss (hypocortisolism). Rare enzyme blocks like 17α‑hydroxylase deficiency can show low 17‑OHP with hypertension, low potassium, delayed puberty, and underdeveloped sexual characteristics.
When values run high, a bottleneck at 21‑hydroxylase shunts precursors into androgens, as in congenital adrenal hyperplasia. Infants may present with virilization or salt‑wasting; children with early pubic hair and rapid growth; women with hirsutism, acne, irregular menses, or infertility; men with early puberty or testicular adrenal rest tissue. Mild, persistent elevations suggest nonclassic CAH; marked spikes can occur with adrenal tumors or physiologically in the luteal phase and pregnancy.
Low values usually reflect reduced adrenal drive or steroidogenesis, such as low pituitary ACTH, prior glucocorticoid exposure, or sampling during a naturally low-output time (early follicular phase in menstruating women). System effects can mirror lower downstream androgens and cortisol—fatigue, low blood pressure, or hypoglycemia—though an isolated low 17-OHP is rarely pathologic by itself and must be read in clinical context.
High values usually reflect impaired 21-hydroxylase activity causing precursor buildup and androgen shunting, as in congenital adrenal hyperplasia (classic or nonclassic). Effects often include acne, hirsutism, irregular cycles, subfertility, or virilization; in newborns, severe forms can cause salt-wasting, dehydration, and ambiguous genital development in XX infants. Levels also rise physiologically in the luteal phase, during pregnancy, with stress/illness, in preterm infants, and with some adrenal or ovarian tumors.
Timing, Drugs, and Assay Method Move 17-OHP
Interpret by time of day (morning higher), menstrual phase, pregnancy, neonatal age, and illness. Glucocorticoids suppress values; some progestins and anticonvulsants can raise them. Assay methods vary; LC–MS/MS is more specific than immunoassays. ACTH stimulation testing helps with borderline results.
Companion Hormones That Sharpen the 17-OHP Picture
17‑OHP links the hypothalamic‑pituitary‑adrenal axis to sex‑steroid biology. Interpreted with ACTH, cortisol, DHEA‑S, androstenedione, and timing information, it helps clarify adrenal integrity, androgen excess states, and long‑term risks for metabolic, reproductive, and bone health.
What a 17-OHP Result Can Clarify
Being in range suggests intact adrenal enzymatic flow through the 21-hydroxylase pathway, with balanced cortisol and androgen output that supports stable energy, blood pressure, and reproductive function. Outside pregnancy and the luteal phase, many adults sit in the low-to-mid portion of the reference interval. Measuring 17-hydroxyprogesterone helps clinicians understand adrenal enzyme function and the balance between stress-hormone and androgen production across different life stages.
FAQs
17-hydroxyprogesterone (17‑OHP) is a steroid intermediate produced mainly in the adrenal cortex and, to a lesser extent, in the ovaries and testes. It acts as a precursor in the synthesis of cortisol and androgens, making it a key marker for adrenal function. Measuring 17‑OHP helps screen for congenital adrenal hyperplasia (CAH), assess adrenal enzyme activity, and clarify causes of symptoms like hirsutism, acne, or irregular periods. Its levels provide insight into the balance of adrenal steroidogenesis and can guide diagnosis and management of hormone-related disorders.
17‑hydroxyprogesterone testing is central to evaluating CAH, especially forms caused by 21‑hydroxylase deficiency. In classic CAH, 17‑OHP levels are markedly elevated due to a bottleneck in cortisol synthesis, leading to excess androgen production. Newborn screening programs routinely measure 17‑OHP to detect CAH early, is studied for its potential effects on life-threatening salt-wasting crises. In milder, nonclassic CAH, moderate elevations help explain symptoms like acne, hirsutism, and irregular periods. Testing also helps differentiate CAH from other causes of androgen excess, such as polycystic ovary syndrome (PCOS).
High 17‑hydroxyprogesterone levels usually indicate a block in the 21‑hydroxylase enzyme, leading to accumulation of 17‑OHP and increased androgen production. This is characteristic of both classic and nonclassic CAH. Other causes include high ACTH states (stress, illness), the luteal phase of the menstrual cycle, pregnancy, and, less commonly, adrenal or ovarian tumors. Elevated 17‑OHP can result in symptoms like acne, hirsutism, irregular cycles, and subfertility. In infants, very high levels signal risk for salt-wasting crises and virilization.
Low 17‑hydroxyprogesterone levels typically reflect reduced adrenal or ovarian steroid production or suppression of ACTH, such as after glucocorticoid therapy. This can be seen in adrenal insufficiency, where symptoms may include fatigue, low blood pressure, dizziness, and salt craving. In healthy children and during the early follicular phase of the menstrual cycle, low levels are normal. Rarely, 17‑hydroxylase deficiency can cause very low 17‑OHP, leading to low sex steroids and hypertension.
Both CAH and PCOS can present with androgen excess symptoms like hirsutism and irregular periods. However, 17‑hydroxyprogesterone testing helps differentiate the two: persistently high 17‑OHP, especially after ACTH stimulation, points toward CAH (usually 21‑hydroxylase deficiency), while normal or only mildly elevated levels are more typical of PCOS. This distinction is crucial for guiding appropriate treatment and management strategies.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., & White, P. C. (2018). Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 103(11), 4043-4088. https://doi.org/10.1210/jc.2018-01865
- Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., & Torpy, D. J. (2016). Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 101(2), 364-389. https://doi.org/10.1210/jc.2015-1710
- Teede, H. J., Tay, C. T., Laven, J., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 120(4), 767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025
- Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007). Position statement: Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. The Journal of Clinical Endocrinology & Metabolism, 92(2), 405-413. https://doi.org/10.1210/jc.2006-1864
- Marques, P., De Sousa Lages, A., Skorupskaite, K., Rozario, K. S., Anderson, R. A., & George, J. T. (2024). Physiology of GnRH and gonadotrophin secretion. In Endotext. MDText.com. https://www.ncbi.nlm.nih.gov/books/NBK279070/
.avif)
.svg)
.svg)
